242 related articles for article (PubMed ID: 34108527)
1. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.
Sun Q; Guo Y; Liu X; Czauderna F; Carr MI; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2019 Dec; 17(12):2457-2468. PubMed ID: 31551253
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Gordhandas SB; Manning-Geist B; Henson C; Iyer G; Gardner GJ; Sonoda Y; Moore KN; Aghajanian C; Chui MH; Grisham RN
Sci Rep; 2022 Jan; 12(1):974. PubMed ID: 35046420
[TBL] [Abstract][Full Text] [Related]
5. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
6. DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.
Carr MI; Zimmermann A; Chiu LY; Zenke FT; Blaukat A; Vassilev LT
Front Oncol; 2020; 10():127. PubMed ID: 32117773
[TBL] [Abstract][Full Text] [Related]
7. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Carr MI; Chiu LY; Guo Y; Xu C; Lazorchak AS; Yu H; Qin G; Qi J; Marelli B; Lan Y; Sun Q; Czauderna F; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2022 Apr; 20(4):568-582. PubMed ID: 34980594
[TBL] [Abstract][Full Text] [Related]
8. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
9. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
Agarwal P; Jackson SP
Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.
Murray HC; Miller K; Brzozowski JS; Kahl RGS; Smith ND; Humphrey SJ; Dun MD; Verrills NM
Mol Cell Proteomics; 2023 Mar; 22(3):100503. PubMed ID: 36682716
[TBL] [Abstract][Full Text] [Related]
11. Orphan receptor TR3 enhances p53 transactivation and represses DNA double-strand break repair in hepatoma cells under ionizing radiation.
Zhao BX; Chen HZ; Du XD; Luo J; He JP; Wang RH; Wang Y; Wu R; Hou RR; Hong M; Wu Q
Mol Endocrinol; 2011 Aug; 25(8):1337-50. PubMed ID: 21659476
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
Samuels M; Falkenius J; Bar-Ad V; Dunst J; van Triest B; Yachnin J; Rodriguez-Gutierrez A; Kuipers M; You X; Sarholz B; Locatelli G; Becker A; Troost EGC
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):743-756. PubMed ID: 37751793
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
14. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
15. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
16. Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy.
Matsumoto Y
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457081
[TBL] [Abstract][Full Text] [Related]
17. AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells.
Lapa BS; Costa MI; Figueiredo D; Jorge J; Alves R; Monteiro AR; Serambeque B; Laranjo M; Botelho MF; Carreira IM; Sarmento-Ribeiro AB; Gonçalves AC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895013
[TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
Patterson-Fortin J; Bose A; Tsai WC; Grochala C; Nguyen H; Zhou J; Parmar K; Lazaro JB; Liu J; McQueen K; Shapiro GI; Kozono D; D'Andrea AD
Cancer Res; 2022 Oct; 82(20):3815-3829. PubMed ID: 35972384
[TBL] [Abstract][Full Text] [Related]
20. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
